共查询到20条相似文献,搜索用时 31 毫秒
1.
2.
Maddatu TP Garvey SM Schroeder DG Zhang W Kim SY Nicholson AI Davis CJ Cox GA 《Human molecular genetics》2005,14(21):3179-3189
Mutations in the immunoglobulin mu binding protein-2 (Ighmbp2) gene cause motor neuron disease and dilated cardiomyopathy (DCM) in the neuromuscular degeneration (nmd) mouse and spinal muscular atrophy with respiratory distress (SMARD1) in humans. To investigate the role of IGHMBP2 in the pathogenesis of DCM, we generated transgenic mice expressing the full-length Ighmbp2 cDNA specifically in myocytes under the control of the mouse titin promoter. This tissue-specific transgene increased the lifespan of nmd mice up to 8-fold by preventing primary DCM and showed complete functional correction as measured by ECG, echocardiography and plasma creatine kinase-MB. Double-transgenic nmd mice expressing Ighmbp2 both in myocytes and in neurons display correction of both DCM and motor neuron disease, resulting in an essentially wild-type appearance. Additionally, quantitative trait locus (QTL) analysis was undertaken to identify genetic modifier loci responsible for the preservation of cardiac function and a marked delay in the onset of cardiomyopathy in a CAST/EiJ backcross population. Three major CAST-derived cardiac modifiers of nmd were identified on chromosomes 9, 10 and 16, which account for over 26% of the genetic variance and that continue to suppress the exacerbation of cardiomyopathy, otherwise resulting in early death, as incipient B6.CAST congenics. Overall, our results verify the tissue-specific requirement for IGHMBP2 in cardiomyocyte maintenance and survival and describe genetic modifiers that can alter the course of DCM through cardiac functional adaptation and physical remodeling in response to changes in load and respiratory demand. 相似文献
3.
Ruiz R Lin J Forgie A Foletti D Shelton D Rosenthal A Tabares L 《Human molecular genetics》2005,14(13):1825-1837
Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is a fatal autosomal recessive disorder seen in infants. It is characterized by lower motor neuron degeneration, progressive muscle paralysis and respiratory failure, for which no effective treatment exists. The phenotype of neuromuscular degeneration (nmd) mice closely resembles the human SMARD1. The identification of the mutated mouse gene in nmd mice, Ighmbp2, led to the discovery of mutations of the homologous gene in humans with SMARD1. We have studied the nmd mouse model with in vivo electrophysiological techniques and evaluated the efficacy of Mab2256, a monoclonal antibody with agonist effect on the tyrosine kinase receptor C, trkC, on disease progression in nmd mice. Treatment with Mab2256 resulted in a significant but transient improvement of muscle strength in nmd mice, as well as normalization of the neuromuscular depression during high-frequency nerve stimulation. These results suggest the potential of using monoclonal agonist antibodies for neurotrophin receptors in lower motor neuron diseases such as SMARD1. 相似文献
4.
Transplanted ALDHhiSSClo neural stem cells generate motor neurons and delay disease progression of nmd mice, an animal model of SMARD1 总被引:1,自引:0,他引:1
Corti S Locatelli F Papadimitriou D Donadoni C Del Bo R Crimi M Bordoni A Fortunato F Strazzer S Menozzi G Salani S Bresolin N Comi GP 《Human molecular genetics》2006,15(2):167-187
5.
Spinal muscular atrophy (SMA) is caused by mutation of the Survival Motor Neurons 1 (SMN1) gene and is characterized by degeneration of spinal motor neurons. The severity of SMA is primarily influenced by the copy number of the SMN2 gene. Additional modifier genes that lie outside the SMA locus exist and one gene that could modify SMA is the Zinc Finger Protein (ZPR1) gene. To test the significance of ZPR1 downregulation in SMA, we examined the effect of reduced ZPR1 expression in mice with mild and severe SMA. We report that the reduced ZPR1 expression causes increase in the loss of motor neurons, hypermyelination in phrenic nerves, increase in respiratory distress and disease severity and reduces the lifespan of SMA mice. The deficiency of SMN-containing sub-nuclear bodies correlates with the severity of SMA. ZPR1 is required for the accumulation of SMN in sub-nuclear bodies. Further, we report that ZPR1 overexpression increases levels of SMN and promotes accumulation of SMN in sub-nuclear bodies in SMA patient fibroblasts. ZPR1 stimulates neurite growth and rescues axonal growth defects in SMN-deficient spinal cord neurons from SMA mice. These data suggest that the severity of disease correlates negatively with ZPR1 levels and ZPR1 may be a protective modifier of SMA. 相似文献
6.
Therapeutic benefits of cardiotrophin-1 gene transfer in a mouse model of spinal muscular atrophy 总被引:9,自引:0,他引:9
Lesbordes JC Cifuentes-Diaz C Miroglio A Joshi V Bordet T Kahn A Melki J 《Human molecular genetics》2003,12(11):1233-1239
Spinal muscular atrophy (SMA) is a recessive autosomal disorder characterized by degeneration of lower motor neurons caused by mutations of the survival motor neuron gene (SMN1). No curative treatment is known so far. Mutant mice carrying homozygous deletion of Smn exon 7 directed to neurons display skeletal muscle denervation, moderate loss of motor neuron cell bodies and severe axonal degeneration. These features, similar to those found in human SMA, strongly suggest the involvement of a dying back process of motor neurons and led us to test whether neurotrophic factors might have a protective role in SMA. We report here the therapeutic benefits of systemic delivery of cardiotrophin-1 (CT-1), a neurotrophic factor belonging to the IL-6 cytokine family. Intra-muscular injection of adenoviral vector expressing CT-1, even at very low dose, improves median survival, delays motor defect of mutant mice and exerts protective effect against loss of proximal motor axons and aberrant cytoskeletal organization of motor synaptic terminals. In spite of the severity of SMA phenotype in mutant mice, CT-1 is able to slow down disease progression. Neuroprotection could be regarded as valuable therapeutic approach in SMA. 相似文献
7.
Spinal muscular atrophy (SMA) is caused by reduced levels of survival motor neuron (SMN) protein. Previously, cultured SMA motor neurons showed reduced growth cone size and axonal length. Furthermore, reduction of SMN in zebrafish resulted in truncation followed by branching of motor neuron axons. In this study, motor neurons labeled with green fluorescent protein (GFP) were examined in SMA mice from embryonic day 10.5 to postnatal day 2. SMA motor axons showed no defect in axonal formation or outgrowth at any stage of development. However, a significant increase in synapses lacking motor axon input was detected in embryonic SMA mice. Therefore, one of the earliest detectable morphological defects in the SMA mice is the loss of synapse occupation by motor axons. This indicates that in severe SMA mice there are no defects in motor axon formation however, we find evidence of denervation in embryogenesis. 相似文献
8.
Neurofilament accumulation at the motor endplate and lack of axonal sprouting in a spinal muscular atrophy mouse model 总被引:6,自引:0,他引:6
Cifuentes-Diaz C Nicole S Velasco ME Borra-Cebrian C Panozzo C Frugier T Millet G Roblot N Joshi V Melki J 《Human molecular genetics》2002,11(12):1439-1447
Mutations of survival of the motor neuron gene (SMN1) are responsible for spinal muscular atrophy (SMA), a common genetic cause of death in childhood. The cellular mechanism by which mutations of SMN1 are responsible for the selective neuromuscular defect and motor neuron cell degeneration observed in SMA has not been described. We have previously generated mice carrying a homozygous deletion of Smn exon 7 directed to neurons. We report here that these mutant mice display a dramatic and progressive loss of motor axons involving both proximal and terminal regions, in agreement with the skeletal muscle denervation process and disease progression. Moreover, we found massive accumulation of neurofilaments, including phosphorylated forms, in terminal axons of the remaining neuromuscular junctions. This aberrant cytoskeletal organization of synaptic terminals was associated with reduction of branched structures of the postsynaptic apparatus and defect of axonal sprouting in mutant mice. Together, these findings may be responsible for severe motor neuron dysfunction, and suggest that loss of motor neuron cell bodies results from a 'dying-back' axonopathy in SMA. Smn mutant mice should represent a valuable model for elucidating the pathway linking Smn to cytoskeletal organization. 相似文献
9.
10.
Spinal muscular atrophy (SMA) is a progressive disease involving the degeneration of motor neurons with no currently available
treatment. While valproic acid (VPA) is a potential treatment for SMA, its therapeutic mechanisms are still controversial.
In this study, we investigated the mechanisms of action of VPA in the treatment of type III-like SMA mice. SMA and wild-type
mice were treated with VPA from 6 to 12 months and 10 to 12 months of age, respectively. Untreated SMA littermates and age-matched
wild-type mice were used for comparison. VPA-treated SMA mice showed better motor function, larger motor-evoked potentials,
less degeneration of spinal motor neurons, less muscle atrophy, and better neuromuscular junction innervation than non-treated
SMA mice. VPA elevated SMN protein levels in the spinal cord through SMN2 promoter activation and probable restoration of correct splicing of SMN2 pre-messenger RNA. VPA also increased levels of anti-apoptotic factors, Bcl-2 and Bcl-xL, in spinal neurons. VPA probably induced neurogenesis and promoted astrocyte proliferation in the spinal cord of type III-like
SMA mice, which might contribute to therapeutic effects by enhancing neuroprotection. Through these effects of elevation of
SMN protein level, anti-apoptosis, and probable neuroprotection, VPA-treated SMA mice had less degeneration of spinal motor
neurons and better motor function than untreated type III-like SMA mice.
Electronic supplementary material The online version of this article (doi:) contains supplementary material, which is available to authorized users. 相似文献
11.
Selective loss of alpha motor neurons with sparing of gamma motor neurons and spinal cord cholinergic neurons in a mouse model of spinal muscular atrophy
下载免费PDF全文
![点击此处可从《Journal of anatomy》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Spinal muscular atrophy (SMA) is a neuromuscular disease characterised primarily by loss of lower motor neurons from the ventral grey horn of the spinal cord and proximal muscle atrophy. Recent experiments utilising mouse models of SMA have demonstrated that not all motor neurons are equally susceptible to the disease, revealing that other populations of neurons can also be affected. Here, we have extended investigations of selective vulnerability of neuronal populations in the spinal cord of SMA mice to include comparative assessments of alpha motor neuron (α‐MN) and gamma motor neuron (γ‐MN) pools, as well as other populations of cholinergic neurons. Immunohistochemical analyses of late‐symptomatic SMA mouse spinal cord revealed that numbers of α‐MNs were significantly reduced at all levels of the spinal cord compared with controls, whereas numbers of γ‐MNs remained stable. Likewise, the average size of α‐MN cell somata was decreased in SMA mice with no change occurring in γ‐MNs. Evaluation of other pools of spinal cord cholinergic neurons revealed that pre‐ganglionic sympathetic neurons, central canal cluster interneurons, partition interneurons and preganglionic autonomic dorsal commissural nucleus neuron numbers all remained unaffected in SMA mice. Taken together, these findings indicate that α‐MNs are uniquely vulnerable among cholinergic neuron populations in the SMA mouse spinal cord, with γ‐MNs and other cholinergic neuronal populations being largely spared. 相似文献
12.
Jablonka S Karle K Sandner B Andreassi C von Au K Sendtner M 《Human molecular genetics》2006,15(3):511-518
Motor neuron degeneration is the predominant pathological feature of spinal muscular atrophy (SMA). In patients with severe forms of the disease, additional sensory abnormalities have been reported. However, it is not clear whether the loss of sensory neurons is a common feature in severe forms of the disease, how many neurons are lost and how loss of sensory neurons compares with motor neuron degeneration. We have analysed dorsal root ganglionic sensory neurons in Smn-/-;SMN2 mice, a model of type I SMA. In contrast to lumbar motor neurons, no loss of sensory neurons in the L5 dorsal root ganglia is found at post-natal days 3-5 when these mice are severely paralyzed and die from motor defects. Survival of cultured sensory neurons in the presence of NGF and other neurotrophic factors is not reduced in comparison to wild-type controls. However, isolated sensory neurons have shorter neurites and smaller growth cones, and beta-actin protein and beta-actin mRNA are reduced in sensory neurite terminals. In footpads of Smn-deficient mouse embryos, sensory nerve terminals are smaller, suggesting that Smn deficiency reduces neurite outgrowth during embryogenesis. These data indicate that pathological alterations in severe forms of SMA are not restricted to motor neurons, but the defects in the sensory neurons are milder than those in the motor neurons. 相似文献
13.
Guenther UP Varon R Schlicke M Dutrannoy V Volk A Hübner C von Au K Schuelke M 《Human mutation》2007,28(8):808-815
Autosomal recessive spinal muscular atrophy with respiratory distress (SMARD) is a heterogeneous disorder. Mutations in the immunoglobulin micro-binding protein gene (IGHMBP2) lead to SMARD1, but clinical criteria that delineate SMARD1 from other SMARD syndromes are not well established. Here we present a retrospective clinical and genetic study to determine the criteria that would predict the presence or absence of IGHMBP2 mutations. From 141 patients with respiratory distress and a spinal muscular atrophy phenotype we recorded the clinical features through a questionnaire and sequenced the entire coding region of IGHMBP2. In 47 (33%) patients we identified IGHMBP2 mutations, 14 of which were not described before. Clinical features and combinations thereof associated with the presence of IGHMBP2 mutations were discovered through hierarchical cluster analysis. This method detects common traits not evident at first sight by grouping items according to their similarity. The combination of "manifestation of respiratory failure between 6 weeks and 6 months" AND ("presence of diaphragmatic eventration" OR "preterm birth") predicted the presence of IGHMBP2 mutations with 98% sensitivity and 92% specificity. Non-SMARD1 patients fell into two different symptom clusters, mainly separated by the age at respiratory failure and the presence of multiple congenital contractures. The 14 novel IGHMBP2 mutations comprised missense, frameshift, splice-site, and nonsense mutations. All missense mutations altered conserved residues within or adjacent to the putative DNA helicase domain. The c.1235+3A>G splice-site mutation did not entirely suppress correct splicing and we found a residual wild-type IGHMBP2 mRNA steady-state level of 24.4+/-6.9%, which was, however, not sufficient to avert SMARD1 in this patient. 相似文献
14.
Mutsaers CA Wishart TM Lamont DJ Riessland M Schreml J Comley LH Murray LM Parson SH Lochmüller H Wirth B Talbot K Gillingwater TH 《Human molecular genetics》2011,20(22):4334-4344
Low levels of full-length survival motor neuron (SMN) protein cause the motor neuron disease, spinal muscular atrophy (SMA). Although motor neurons undoubtedly contribute directly to SMA pathogenesis, the role of muscle is less clear. We demonstrate significant disruption to the molecular composition of skeletal muscle in pre-symptomatic severe SMA mice, in the absence of any detectable degenerative changes in lower motor neurons and with a molecular profile distinct from that of denervated muscle. Functional cluster analysis of proteomic data and phospho-histone H2AX labelling of DNA damage revealed increased activity of cell death pathways in SMA muscle. Robust upregulation of voltage-dependent anion-selective channel protein 2 (Vdac2) and downregulation of parvalbumin in severe SMA mice was confirmed in a milder SMA mouse model and in human patient muscle biopsies. Molecular pathology of skeletal muscle was ameliorated in mice treated with the FDA-approved histone deacetylase inhibitor, suberoylanilide hydroxamic acid. We conclude that intrinsic pathology of skeletal muscle is an important and reversible event in SMA and also suggest that muscle proteins have the potential to act as novel biomarkers in SMA. 相似文献
15.
Maystadt I Zarhrate M Landrieu P Boespflug-Tanguy O Sukno S Collignon P Melki J Verellen-Dumoulin C Munnich A Viollet L 《Human mutation》2004,23(5):525-526
Spinal Muscular Atrophy with Respiratory Distress (SMARD) is an autosomal recessive disorder characterized by neurogenic muscular atrophy due to progressive anterior horn cell degeneration and early life-threatening respiratory failure ascribed to diaphragmatic dysfunction. SMARD is clinically and genetically heterogeneous. SMARD type 1 is characterized by onset of respiratory failure within the first weeks of life and has been ascribed to mutations in the immunoglobulin mu-binding protein 2 (IGHMBP2) gene on chromosome 11q13-q21. We report here the identification of nine novel IGHMBP2 mutations in five SMARD1 patients, including seven missense [ c.587A>G (p.Gln196Arg), c.647C>T (p.Pro216Leu), c.752T>C (p.Leu251Pro), c.1693G>A (p.Asp565Asn), c.1730T>C (p.Leu577Pro), c.1807C>T (p.Arg603Cys), c.1909C>T (p.Arg637Cys)] and two nonsense mutations [ c.1488C>A (p.Cys496X), c.2368C>T (p.Arg790X)]. Interestingly, 7 of 9 mutations occurred at highly conserved residues of the putative DNA helicase domain. The identification of novel IGHMBP2 variants will hopefully help diagnosing SMARD1 and contribute to a better functional characterization of IGHMBP2 gene product. 相似文献
16.
Co-regulation of survival of motor neuron (SMN) protein and its interactor SIP1 during development and in spinal muscular atrophy 总被引:2,自引:0,他引:2
Jablonka S Bandilla M Wiese S Bühler D Wirth B Sendtner M Fischer U 《Human molecular genetics》2001,10(5):497-505
Spinal muscular atrophy (SMA) is a neuromuscular disease characterized by the degeneration of motor neurons in the spinal cord. The disease is caused by mutations of the survival of motor neuron 1 gene (SMN1), resulting in a reduced production of functional SMN protein. A major question unanswered thus far is why reduced amounts of ubiquitously expressed SMN protein specifically cause the degeneration of motor neurons without affecting other somatic cell types. In a first attempt to address this issue we have investigated the Smn interacting protein 1 (Sip1), with an emphasis on its developmental expression and subcellular distribution in spinal motor neurons in relation to Smn. By confocal immunofluorescence studies we provide evidence that a significant amount of Smn does not co-localize with Sip1 in neurites of motor neurons, indicating that Smn may exert motor neuron-specific functions that are not dependent on Sip1. Sip1 is highly expressed in the spinal cord during early development and expression decreases in parallel with Smn during postnatal development. Strikingly, reduced production of Smn as observed in cell lines derived from SMA patients or in a mouse model for SMA coincides with a simultaneous reduction of Sip1. The finding that expression of Sip1 and Smn is tightly co-regulated, together with the unique localization of Smn in neurites, may help in understanding the motor neuron-specific defects observed in SMA patients. 相似文献
17.
The distribution of SMN protein complex in human fetal tissues and its alteration in spinal muscular atrophy 总被引:1,自引:8,他引:1
Burlet P; Huber C; Bertrandy S; Ludosky MA; Zwaenepoel I; Clermont O; Roume J; Delezoide AL; Cartaud J; Munnich A; Lefebvre S 《Human molecular genetics》1998,7(12):1927-1933
Spinal muscular atrophy (SMA) is a common autosomal recessive neuromuscular
disorder characterized by degeneration of motor neurons of the spinal cord
and muscular atrophy. SMA is caused by alterations to the survival of motor
neuron (SMN) gene, the function of which has hitherto been unclear. Here,
we present immunoblot analyses showing that normal SMN protein expression
undergoes a marked decay in the postnatal period compared with fetal
development. Morphological and immunohistochemical analyses of the SMN
protein in human fetal tissues showed a general distribution in the
cytoplasm, except in muscle cells, where SMN protein was immunolocalized to
large cytoplasmic dot-like structures and was tightly associated with
membrane-free heavy sedimenting complexes. These cytoplasmic structures
were similar in size to gem. The SMN protein was markedly deficient in
tissues derived from type I SMA fetuses, including skeletal muscles and, as
previously shown, spinal cord. While our data do not help decide whether
SMA results from impaired SMN expression in spinal cord, skeletal muscle or
both, they suggest a requirement for SMN protein during embryo-fetal
development.
相似文献
18.
Yimin Hua Ying Hsiu Liu Kentaro Sahashi Frank Rigo C. Frank Bennett Adrian R. Krainer 《Genes & development》2015,29(3):288-297
Survival of motor neuron (SMN) deficiency causes spinal muscular atrophy (SMA), but the pathogenesis mechanisms remain elusive. Restoring SMN in motor neurons only partially rescues SMA in mouse models, although it is thought to be therapeutically essential. Here, we address the relative importance of SMN restoration in the central nervous system (CNS) versus peripheral tissues in mouse models using a therapeutic splice-switching antisense oligonucleotide to restore SMN and a complementary decoy oligonucleotide to neutralize its effects in the CNS. Increasing SMN exclusively in peripheral tissues completely rescued necrosis in mild SMA mice and robustly extended survival in severe SMA mice, with significant improvements in vulnerable tissues and motor function. Our data demonstrate a critical role of peripheral pathology in the mortality of SMA mice and indicate that peripheral SMN restoration compensates for its deficiency in the CNS and preserves motor neurons. Thus, SMA is not a cell-autonomous defect of motor neurons in SMA mice. 相似文献
19.
The survival motor neuron protein in spinal muscular atrophy 总被引:19,自引:1,他引:19
Coovert DD; Le TT; McAndrew PE; Strasswimmer J; Crawford TO; Mendell JR; Coulson SE; Androphy EJ; Prior TW; Burghes AH 《Human molecular genetics》1997,6(8):1205-1214
The 38 kDa survival motor neuron (SMN) protein is encoded by two
ubiquitously expressed genes: telomeric SMN (SMN(T)) and centromeric SMN
(SMN(C)). Mutations in SMN(T), but not SMN(C), cause proximal spinal
muscular atrophy (SMA), an autosomal recessive disorder that results in
loss of motor neurons. SMN is found in the cytoplasm and nucleus. The
nuclear form is located in structures termed gems. Using a panel of
anti-SMN antibodies, we demonstrate that the SMN protein is expressed from
both the SMN(T) and SMN(C) genes. Western blot analysis of fibroblasts from
SMA patients with various clinical severities of SMA showed a moderate
reduction in the amount of SMN protein, particularly in type I (most
severe) patients. Immunocytochemical analysis of SMA patient fibroblasts
indicates a significant reduction in the number of gems in type I SMA
patients and a correlation of the number of gems with clinical severity.
This correlation to phenotype using primary fibroblasts may serve as a
useful diagnostic tool in an easily accessible tissue. SMN is expressed at
high levels in brain, kidney and liver, moderate levels in skeletal and
cardiac muscle, and low levels in fibroblasts and lymphocytes. In SMA
patients, the SMN level was moderately reduced in muscle and lymphoblasts.
In contrast, SMN was expressed at high levels in spinal cord from normals
and non- SMA disease controls, but was reduced 100-fold in spinal cord from
type I patients. The marked reduction of SMN in type I SMA spinal cords is
consistent with the features of this motor neuron disease. We suggest that
disruption of SMN(T) in type I patients results in loss of SMN from motor
neurons, resulting in the degeneration of these neurons.
相似文献
20.
Boda B Mas C Giudicelli C Nepote V Guimiot F Levacher B Zvara A Santha M LeGall I Simonneau M 《European journal of human genetics : EJHG》2004,12(9):729-737
Spinal muscular atrophy (SMA) is a recessive disorder involving the loss of motor neurons from the spinal cord. Homozygous absence of the survival of motor neuron 1 gene (SMN1) is the main cause of SMA, but disease severity depends primarily on the number of SMN2 gene copies. SMN protein levels are high in normal spinal cord and much lower in the spinal cord of SMA patients, suggesting neuron-specific regulation for this ubiquitously expressed gene. We isolated genomic DNA from individuals with SMN1 or SMN2 deletions and sequenced 4.6 kb of the 5' upstream regions of the these. We found that these upstream regions, one of which is telomeric and the other centromeric, were identical. We investigated the early regulation of SMN expression by transiently transfecting mouse embryonic spinal cord and fibroblast primary cultures with three transgenes containing 1.8, 3.2 and 4.6, respectively, of the SMN promoter driving beta-galactosidase gene expression. The 4.6 kb construct gave reporter gene expression levels five times higher in neurons than in fibroblasts, due to the combined effects of a general enhancer and a non-neuronal cell silencer. The differential expression observed in neurons and fibroblasts suggests that the SMN genes play a neuron-specific role during development. An understanding of the mechanisms regulating SMN promoter activity may provide new avenues for the treatment of SMA. 相似文献